Accelerating Discovery of Kinase Inhibitors Using an ADP Assay
Tuesday, 23 February 2021
An ADP assay can be used to study the activity of enzymes that phosphorylate substrates leading to signaling events in the body. One of a variety of post-translational modifications, protein phosphorylation regulates a diverse group of cellular functions. In cancer, abnormal phosphorylation events often play a role in proliferation, survival, motility, metabolism, and angiogenesis.1 PI3K
- Published in HTS Assays
No Comments
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1
Thursday, 11 February 2021
BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the
- Published in Emerging Targets, HTS Assays, News
Using a Universal GMP Assay for PDE Research
Thursday, 28 January 2021
A universal GMP assay to aid in PDE research and potential COVID-19 disruption. – Phosphodiesterase enzymes (PDEs) modulate pathways throughout the body. Since unregulated PDEs contribute to disease in many cases, it makes sense therapies that inhibit these enzymes have the potential to treat several different ailments. These include cardiovascular and respiratory issues, diabetes, fibrotic
- Published in HTS Assays, Uncategorized
Join Us for SLAS 2021 Virtual Conference
Wednesday, 13 January 2021
BellBrook Labs will be exhibiting at SLAS 2021, January 25-27. Due to the pandemic, this year’s meeting will, of course, be virtual. Although, we are sad that we won’t be able to meet with you in person this year there are still plenty of opportunities to interact. We will have a virtual booth that is
New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay
Thursday, 10 December 2020
Launched in November 2019, the Transcreener cGAMP cGAS Assay has generated a great deal of interest in the drug discovery community. While fluorescence polarization (FP) readouts offer a stable and robust option, some researchers prefer time-resolved Förster-resonance-energy-transfer (TR-FRET) readouts for large screens. After months of development, BellBrook Labs is pleased to announce the addition of
Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay
Wednesday, 28 October 2020
The immune system uses the recognition of foreign nucleic acids and subsequent type I interferon production as a first line of defense in response to microbial invaders. Recent research has validated one key to this cascade, a unique cyclic dinucleotide – cGAMP. The enzyme cGAS produces this recently discovered molecular messenger. As an apoenzyme, cGAS
- Published in News
Five Considerations When Choosing a Biochemical Assay Development Services CRO
Monday, 28 September 2020
There are many options out there for choosing assay development services, and finding what you need can be a challenging endeavor. Here we outline five items to look for when searching for the CRO that is right for your project. To narrow things down a bit, this article will focus on biochemical assay development services
- Published in Resources
Battling Autoimmune Disorders Using JAK1 Inhibitors
Wednesday, 12 August 2020
Could specific JAK1 inhibitors lead to better treatments for autoimmune disease? – The human immune response is complex with numerous cellular pathways playing a role. And, when an abnormal immune response results from one’s own body, known as an autoimmune disorder – it adds to the complexity. While we often think of celiac disease, inflammatory
- Published in HTS Assays, News
A Search for NLRP3 Inhibitors to Fight Autoimmune Disease
Wednesday, 08 July 2020
Can NLRP3 inhibitors help treat autoimmune disease? – The human immune response is complicated and we continue to discover pathways involved that add to the complexity. Different than the adaptive immune response, the innate response acts quickly and is considered the first line of defense against pathogens and foreign DNA. In order to do its
- Published in Emerging Targets